Vicapsys Life Sciences, Inc. (VICP)
- Previous Close
0.9799 - Open
0.9799 - Bid --
- Ask --
- Day's Range
0.9799 - 0.9799 - 52 Week Range
0.6000 - 3.0000 - Volume
100 - Avg. Volume
62 - Market Cap (intraday)
31.427M - Beta (5Y Monthly) -5.99
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.
vicapsys.comRelated News
Performance Overview: VICP
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VICP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VICP
Valuation Measures
Market Cap
31.43M
Enterprise Value
31.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-43.93
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-141.85%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.08M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
53.53k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-86.89k
Company Insights: VICP
VICP does not have Company Insights